First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas, Arnaud Scherpereel, Anna K. Nowak et al. · The Lancet · 2021
Cited by 1,205 works. doi:10.1016/s0140-6736(20)32714-8 Open-access PDF
Authors
- Arnaud Scherpereel
- Anna K. Nowak
- Nobukazu Fujimoto
- Solange Peters
- Anne S. Tsao
- Aaron Scott Mansfield
- Sanjay Popat
- Thierry Marie Jahan
- Scott Joseph Antonia
- Youssef Oulkhouir
- Robin Cornelissen
- Laurent Greillier
- Francesco Grossi
- Dariusz Mirosław Kowalski
- Jerónimo Rafael Rodríguez‐Cid
- Praveen Aanur
- Abderrahim Oukessou
- Christine Baudelet
References
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial